Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched control group Clear all
Completed No phase listed Observational Accepts healthy volunteers

Extracellular Signal-Related Kinase Biomarker Development in Autism

NCT01850459
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 25 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

NCT06979518
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Reach Unrestricted Services for Transgender Women

NCT03877497
View directory record Official record
Conditions
Transgender Women, Substance Abuse, Hiv
Interventions
Adapted SBIRT-T for transgender women
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 31, 2026, 1:32 AM EDT
Completed No phase listed Observational

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

NCT02188290
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 31, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Stress Management Program for African American Women

NCT04863781
View directory record Official record
Conditions
Psychological Stress
Interventions
Mobile cognitive-behavioral stress management intervention, Control
Behavioral
Lead sponsor
ISA Associates, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 31, 2026, 1:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
La Jolla, California • Orange, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Active, not recruiting Not applicable Interventional

Durham Connects RCT Evaluation II

NCT01843036
View directory record Official record
Conditions
Unspecified Child Maltreatment, Suspected, Unspecified Child Maltreatment, Confirmed
Interventions
Durham Connects
Other
Lead sponsor
Duke University
Other
Eligibility
Up to 6 Months
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed No phase listed Observational

Surgical Site Infections and the Microbiome: Understanding the Pathogenesis of Surgical Site Infections

NCT06300892
View directory record Official record
Conditions
Open GI Surgery
Interventions
No intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MEMORI Corps: Activity-based Companion Care for Dementia

NCT03896711
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MEMORI Corps program, Augmented Waitlist Control
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 115 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Results available

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

NCT05452239
View directory record Official record
Conditions
Migraine, Medication Overuse Headache
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Winter Haven, Florida • Marrero, Louisiana • Springfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

NCT06451757
View directory record Official record
Conditions
Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Interventions
Sonlicromanol, Placebo
Drug
Lead sponsor
Khondrion BV
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access

NCT02475837
View directory record Official record
Conditions
AV Fistula
Interventions
Vorapaxar sulfate, Placebo
Drug
Lead sponsor
Ken Mahaffey
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 31, 2026, 1:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 31, 2026, 1:32 AM EDT
Completed No phase listed Observational

Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes

NCT02957461
View directory record Official record
Conditions
Brain Injuries, Traumatic, Concussion, Mild, Concussion, Brain, Concussion, Severe, Concussion, Intermediate
Interventions
BrainScope Ahead 200iD
Device
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
18 Years to 25 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fayetteville, Arkansas • Storrs, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

NCT01793441
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RG7314
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

NCT07049939
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Bomedemstat
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 31, 2026, 1:32 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

NCT01473680
View directory record Official record
Conditions
Breast Cancer
Interventions
EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 61 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

NCT02313103
View directory record Official record
Conditions
Renally Impaired Subjects
Interventions
lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 31, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

NCT02131662
View directory record Official record
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 31, 2026, 1:32 AM EDT